<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24216069</article-id><article-id pub-id-type="pmc">4225749</article-id><article-id pub-id-type="publisher-id">1745-6215-14-379</article-id><article-id pub-id-type="doi">10.1186/1745-6215-14-379</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Silva</surname><given-names>Paula S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>paula.simplicio@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Sperandio da Silva</surname><given-names>Gilberto Marcelo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gilberto.silva@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A3"><name><surname>de Souza</surname><given-names>Andr&#x000e9;a P</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>andrea@ioc.fiocruz.br</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Cardoso</surname><given-names>Claudia SA</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>claudia.cardoso@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Fonseca</surname><given-names>Cristiane A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cristiane.fonseca@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Brito</surname><given-names>Patricia D</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>patricia.brito@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Saraiva</surname><given-names>Roberto M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>roberto.saraiva@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Brasil</surname><given-names>Pedro EA</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>pedro.brasil@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Pinheiro</surname><given-names>Roberta O</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>rolmo@ioc.fiocruz.br</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Hasslocher-Moreno</surname><given-names>Alejandro M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>alejandro.hasslocher@ipec.fiocruz.br</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Xavier</surname><given-names>S&#x000e9;rgio S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>sergiosallesx@gmail.com</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Sousa</surname><given-names>Andr&#x000e9;a S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>andrea.silvestre@ipec.fiocruz.br</email></contrib></contrib-group><aff id="I1"><label>1</label>Servi&#x000e7;o de Nutri&#x000e7;&#x000e3;o, Instituto de Pesquisa Cl&#x000ed;nica Evandro Chagas, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brasil</aff><aff id="I2"><label>2</label>Laborat&#x000f3;rio de Pesquisa Cl&#x000ed;nica em Doen&#x000e7;a de Chagas, Instituto de Pesquisa Cl&#x000ed;nica Evandro Chagas, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brasil</aff><aff id="I3"><label>3</label>Laborat&#x000f3;rio de Inova&#x000e7;&#x000f5;es em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brasil</aff><aff id="I4"><label>4</label>Laborat&#x000f3;rio de Hansen&#x000ed;ase, Instituto Oswaldo Cruz, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brasil</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2013</year></pub-date><volume>14</volume><fpage>379</fpage><lpage>379</lpage><history><date date-type="received"><day>5</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Silva et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Silva et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/14/1/379"/><abstract><sec><title>Background</title><p>Chronic chagasic cardiomyopathy is an inflammatory disease that occurs in approximately 30% of patients infected by the protozoan <italic>Trypanosoma cruzi</italic>, and it has a profile of high morbidity and mortality. The worst prognosis and the progression of this cardiomyopathy are associated with an exacerbated immune response and the production of proinflammatory cytokines, which also occur in other cardiomyopathies. Some nutrients, including omega-3 polyunsaturated fatty acids (PUFAs), promote the inhibition and/or stimulation of cytokine production. The objective of this trial is to study the effects of omega-3 PUFA supplementation on the inflammatory response and lipid profile in patients with chronic chagasic cardiomyopathy.</p></sec><sec><title>Methods/Design</title><p>This is a parallel, randomized, placebo-controlled, double-blind clinical trial with 40 patients that will be conducted at a reference unit for Chagas disease patients, where the patients will be selected. The study will include patients with chronic chagasic cardiomyopathy who are 18&#x000a0;years of age or older. The exclusion criteria are (a) ongoing diarrheal disease, (b) inflammatory bowel disease, (c) diabetes or other endocrine disease, (d) use of fibrates, niacin, or statins, (e) use of anti-inflammatory drugs, (f) pregnant and lactating women, (g) use of vitamin, mineral, or omega-3 supplementation during the previous 30&#x000a0;days, (h) hospital admission during the study, and (i) other associated cardiomyopathies. The intervention will be treatment with omega-3 PUFAs at a dose of 3&#x000a0;g/day for 8&#x000a0;weeks, compared to placebo (corn oil). The primary endpoints will be the concentrations of inflammatory markers (interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)&#x003b1;, interferon (IFN)&#x003b3;, and transforming growth factor (TGF)&#x003b2;). Secondary endpoints will be the fasting glucose, lipid, and anthropometric profiles. For statistical analysis, we plan to run either a t test or Wilcoxon test (numerical variables) and Pearson&#x02019;s &#x003c7;<sup>2</sup> or Fisher&#x02019;s exact test (categorical data), as appropriate.</p></sec><sec><title>Discussion</title><p>Evidence suggests that the anti-inflammatory action of omega-3 PUFAs may have beneficial effects on chronic chagasic cardiomyopathy, as shown for other cardiomyopathies, due to improved control of the inflammatory response. At the end of the study, we predict that patients will have lower inflammatory markers and an improved metabolic and anthropometric profile.</p></sec><sec><title>Trial registration</title><p>Current Controlled Trials <ext-link ext-link-type="uri" xlink:href="clinicaltrials.gov/ct2/show/NCT01863576?term=omega-3&#x00026;rank=15">NCT01863576</ext-link></p></sec></abstract><kwd-group><kwd>Chagas disease</kwd><kwd><italic>Trypanosoma cruzi</italic></kwd><kwd>Chronic chagasic cardiomyopathy</kwd><kwd>Omega-3</kwd><kwd>Cytokines</kwd><kwd>Lipid profile</kwd><kwd>Nutritional assessment</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Chagas disease is endemic in Latin American countries, where approximately 8 to 10 million people are infected with <italic>Trypanosoma cruzi</italic>[<xref ref-type="bibr" rid="B1">1</xref>]. In Brazil, the number of infected people is approximately 1.9 million, or 1% of the Brazilian population [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>The etiologic diagnosis of Chagas disease is performed by detection of the parasite by parasitological methods (direct or indirect) and confirmed by two different serological techniques indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Chagas disease has two distinct clinical phases: acute and chronic [<xref ref-type="bibr" rid="B3">3</xref>]. The chronic phase has three forms: indeterminate, cardiac involvement, and/or digestive involvement [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. In most cases, acute disease is not recognized at onset, and the individual remains asymptomatic with no evidence of damage to any organ but with reactive serology for Chagas disease and low parasitemia during the chronic phase [<xref ref-type="bibr" rid="B4">4</xref>]. After two or more decades, 20% to 30% of patients progress to the cardiac stage of the disease, when the majority of the deaths and severe complications related to the disease occur [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. Therefore, chronic chagasic cardiomyopathy (CCC) is an important clinical form of Chagas disease due to its impact on morbidity and its high mortality, worsening of the quality of life, and limitation of the ability to work. It is characterized by a myocarditis with multifocal mononuclear inflammatory infiltrates, varying degrees of fibrosis, constant low-grade tissue parasitism, and low or undetectable parasitemia [<xref ref-type="bibr" rid="B9">9</xref>] and it occurs earlier and more severely in males [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Patients in the chronic cardiac phase may manifest heart failure, ventricular and atrial arrhythmias, atrioventricular blocks, thromboembolism, stroke, and sudden death [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B11">11</xref>], which together carry a high economic and mortality burden.</p><p>Once settled, CCC is progressive and tends worsen due to overlap with inflammation, cell destruction, and fibrosis. Some hypotheses have been proposed to explain the nature of the cardiac inflammatory reaction, mainly persistent heart immune response and reaction to the parasite [<xref ref-type="bibr" rid="B12">12</xref>]. Cytokines are important mediators in the maintenance of the inflammatory process, and they can stimulate or inhibit the immune response [<xref ref-type="bibr" rid="B13">13</xref>]. Among the several cytokines studied in <italic>T. cruzi</italic> infection, interferon &#x003b3; (IFN&#x003b3;) has been associated with host resistance to infection in both experimental models and humans [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Transforming growth factor &#x003b2; (TGF&#x003b2;) production is increased in <italic>T. cruzi</italic> infection, and this increase is most likely related to the fibrotic process observed in CCC [<xref ref-type="bibr" rid="B16">16</xref>]. These results suggest that cytokines play essential roles in controlling CCC morbidity [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>].</p><p>Some nutrients are associated with the inhibition and/or stimulation of cytokine production, including polyunsaturated fatty acids (PUFAs). Omega-3 PUFAs (linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid) are found in vegetables (soy, canola, linseed) and cold-water fish (mackerel, sardines, salmon, herring). PUFAs are precursors to the biosynthesis of several important metabolites, especially eicosanoids (prostaglandins, leukotrienes, thromboxanes, lipoxins, and others), synthesized from arachidonic acid [<xref ref-type="bibr" rid="B20">20</xref>]. Omega-6 PUFAs (such as linoleic acid: 18:2n-6) and omega-3 PUFAs (such as linolenic acid: 18:3n-3) are fundamental to the body and have important roles in cell metabolism, including influencing membrane fluidity, promoting the release of cytokines, and acting as adhesion molecules on macrophages. Thus, changes in their synthesis and metabolism may be associated with endothelial and hemodynamic changes that contribute to the increase in cardiovascular morbidity and mortality [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>The fatty acid composition of inflammatory cells can be modified by increasing the intake of marine <italic>n</italic>-3 fatty acids, which leads to a higher content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). A number of cell culture studies have reported that both EPA and DHA decrease the activation of the transcription factor nuclear factor &#x003ba;B (NF&#x003ba;B) in response to inflammatory stimuli, such as lipopolysaccharide and inflammatory cytokines [<xref ref-type="bibr" rid="B22">22</xref>]. Omega-3 PUFAs reduce arachidonic acid content in cell membranes, resulting in the synthesis of eicosanoids that have weaker inflammatory properties than the eicosanoids derived from omega-6 PUFAs [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Omega-3 supplementation is safe and well tolerated in infectious disease as demonstrated in HIV-infected patients treated with antiretroviral therapy [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>], and on host resistance to infection from <italic>Plasmodium berghei</italic> or <italic>Plasmodium falciparum</italic>, the causative agents of malaria [<xref ref-type="bibr" rid="B26">26</xref>], which like Chagas disease is a parasitic infection.</p><p>Several studies involving supplementation of the diet with marine <italic>n</italic>-3 PUFAs in healthy human volunteers have demonstrated decreased production of tumor necrosis factor &#x003b1; (TNF&#x003b1;), interleukin 1&#x003b2; (IL-1&#x003b2;), IL-2, and IL-6 [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Omega-3 PUFA supplementation for 8&#x000a0;weeks has been associated with an increase of peripheral mononuclear cells with high concentrations of EPA and DHA, which have an immunomodulating effect [<xref ref-type="bibr" rid="B28">28</xref>]. In healthy adults, fish oil supplementation at 5&#x000a0;mL/day for 8&#x000a0;weeks reduced the production of IL-6 but did not change the production of IL-10, TNF&#x003b1;, or IFN&#x003b3; [<xref ref-type="bibr" rid="B29">29</xref>]. Long-chain omega-3 PUFA (EPA and DHA) plasma levels are inversely associated with the risk of sudden death [<xref ref-type="bibr" rid="B30">30</xref>] and may reduce the risk of ischemic heart disease [<xref ref-type="bibr" rid="B31">31</xref>]. EPA and DHA are also involved in the reduction of plasma very-low-density lipoprotein cholesterol (VLDL-c) and triglycerides [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>A study conducted by the Italian group GISSI-HF at 326 cardiology sites and 31 internal medicine sites selected 6,975 patients with heart failure diagnosis to receive 1 daily capsule containing 1&#x000a0;g of omega-3 PUFAs (n&#x02009;=&#x02009;3,494) or placebo (n&#x02009;=&#x02009;3,481) [<xref ref-type="bibr" rid="B33">33</xref>]. The total mortality of the supplemented group was 27%, and that of the placebo group was 29% (adjusted HR 0.91; 95.5% confidence interval (CI) 0.833 to 0.998; <italic>P</italic>&#x02009;=&#x02009;0.041). Hospital admissions due to cardiovascular events were 57% in the omega-3 PUFA group versus 59% in the placebo group (adjusted HR 0.92; 99% CI 0.849 to 0.999; <italic>P</italic>&#x02009;=&#x02009;0.009). The advantages of <italic>n</italic>-3 PUFAs, which were reduced fatal events and hospital admissions from cardiovascular causes, suggest that they have an effect on the mechanisms leading to progression of heart failure [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Supplementation with 1&#x000a0;g/day of omega-3 PUFAs in capsules can decrease cardiovascular events by 10% (death, myocardial infarction, stroke) in coronary arterial disease patients [<xref ref-type="bibr" rid="B34">34</xref>]. Some studies that assessed the effect of omega-3 supplementation on the immune response used EPA and/or DHA at 1&#x000a0;g to 9&#x000a0;g per day, similar to the ingestion levels of Greenland Eskimos: 6 to 14&#x000a0;g/day, corresponding to 2.7% to 6.3% of their total calorie intake. The highest doses can reduce arachidonic acid in peripheral mononuclear cells [<xref ref-type="bibr" rid="B35">35</xref>].</p><p>Studies conducted in heart failure patients have not shown adverse events after omega-3 supplementation [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. In contrast, studies in pregnant women and cancer patients have reported gastrointestinal changes (diarrhea, flatulence, gastroesophageal reflux, nausea), although no differences between the treatment and placebo groups were noted [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>].</p><p>Few studies have evaluated the nutritional status of Chagas patients. Three studies have evaluated patients with the digestive form of the disease. In two of these studies [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>], there was a high prevalence of malnutrition (&#x0003e;60%). The other study evaluated ten patients diagnosed as having megaesophagus, and only one had malnutrition. The others were eutrophic or overweight [<xref ref-type="bibr" rid="B41">41</xref>]. A study performed in S&#x000e3;o Paulo, Brazil, assessed the nutritional state of 66 Chagas patients and found a high prevalence of overweight and obesity (94%) and large waist circumference (55%). The indeterminate form of the disease was the most prevalent and constituted 71% of cases [<xref ref-type="bibr" rid="B42">42</xref>]. There are no reports in the literature on the nutritional assessment of CCC patients.</p><p>Supplementation with omega-3 PUFAs may lead to increased bodyweight in patients with heart cachexia, as reported by a study that assessed 14 patients with severe heart failure supplemented with 8&#x000a0;g/day omega-3 PUFAs or placebo [<xref ref-type="bibr" rid="B43">43</xref>].</p><p>Although several studies have shown the beneficial effects of polyunsaturated fatty acids on inflammatory processes, dyslipidemia, and cardiovascular diseases, there are no reports about food intake and PUFA supplementation in CCC patients. Thus, the objective of this study is to assess the effects of omega-3 PUFA supplementation on the lipid profile and the proinflammatory and anti-inflammatory cytokine profiles in CCC patients.</p></sec><sec><title>Methods/Design</title><sec><title>Study design</title><p>This is a parallel, double-blind, placebo-controlled clinical trial with balanced randomization (1:1).</p></sec><sec><title>Settings</title><p>The proposed clinical trial will be held at a single site, the Evandro Chagas Clinical Research Institute (IPEC), which is one of the technical scientific units of the Oswaldo Cruz Foundation (Fiocruz). IPEC is a 93-year-old institution that is fully dedicated to clinical research on infectious diseases, including Chagas disease. IPEC is a major reference center for Chagas disease research, care, and training.</p></sec><sec><title>Participants (inclusion and exclusion criteria)</title><p>Patients will be recruited from the cardiology ambulatory service at IPEC/Fiocruz, Rio de Janeiro, Brazil, during the period determined for screening until the minimum estimated sample size is reached. All patients had a previous epidemiologic history of Chagas disease confirmed with at least two Chagas serology tests (indirect immunofluorescence and ELISA), and clinical evaluations, electrocardiographic and echocardiographic data obtained recently. Selected patients will be older than 18&#x000a0;years, males and females with CCC at stage B (no heart failure symptoms but with segmental or global left ventricular systolic dysfunction by echocardiogram), stage C (symptomatic heart failure), or stage D (end-stage heart failure), according to the current Brazilian Chagas disease consensus [<xref ref-type="bibr" rid="B3">3</xref>]. The following exclusion criteria will be applied: diarrheal disease; inflammatory bowel syndrome; diagnosis of diabetes or other endocrine pathologies; use of fibrates, niacin, or statins; use of anti-inflammatory drugs; pregnant and lactating women; vitamin mineral or omega-3 supplementation during the previous 30&#x000a0;days; hospital admission during the study; and the presence of cardiomyopathies other than CCC.</p></sec><sec><title>Interventions: omega-3 versus corn oil placebo</title><p>Each participant will receive five omega-3 capsules per day (1.8&#x000a0;g EPA and 1.2&#x000a0;g DHA) or placebo for 8&#x000a0;weeks (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). The omega-3 and corn oil capsules will be provided by Relthy Laborat&#x000f3;rios Ltda. (Brazilian Health Surveillance Agency (Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria (ANVISA)) registration: 6.2582.0022.001-1).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Study flow diagram for omega-3 supplementation in patients with chronic chagasic cardiomyopathy.</p></caption><graphic xlink:href="1745-6215-14-379-1"/></fig></sec><sec><title>Endpoints</title><p>The primary endpoint of this study will be the cytokine profile. IL-1, IL-2, IL-4, IL-6, IL-10, TNF&#x003b1;, IFN&#x003b3;, and TGF&#x003b2; will be measured in the serum of patients using specific sandwich enzyme-linked immunosorbent assays. Capture and detection antibodies will be obtained from eBioscience (San Diego, CA, USA). The tests will be conducted according to the manufacturer&#x02019;s instructions and performed in triplicate.</p><p>The first secondary endpoint will be the lipid profile. Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-c) will be measured with enzymatic colorimetric assays using Siemens reagents on a Siemens Dimension RXL chemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Low-density lipoprotein cholesterol (LDL-c) and VLDL-c will be calculated according to the Friedewald equation [<xref ref-type="bibr" rid="B44">44</xref>].</p><p>Another secondary endpoint of this trial will be anthropometric measures. The anthropometric assessment will consist of body mass index (BMI), waist circumference, tricipital skinfold thickness, and arm circumference [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. BMI will be determined using the standard formula: BMI&#x02009;=&#x02009;weight/height<sup>2</sup>[<xref ref-type="bibr" rid="B47">47</xref>].</p></sec><sec><title>Procedures, follow-up, and data collection</title><p>After patients are selected by cardiologists, they will be seen by study nutritionists, who will explain the study procedures to the patients and administer the free and informed consent form. The patients who agree to participate in the study will sign the consent form and undergo the initial assessment.</p><p>The following data will be collected and evaluated in the study: sociodemographic data (age, sex, ethnicity/race, education, and domicile), clinical data (functional class and vital signs), alcoholism, smoking, prescription drugs, 3-day food record [<xref ref-type="bibr" rid="B48">48</xref>], 24-h recall [<xref ref-type="bibr" rid="B49">49</xref>], anthropometric assessment (height, weight, BMI, waist circumference, tricipital skinfold thickness, and arm circumference), lipid profile (total cholesterol, triglycerides, HDL-c, LDL-c, and VLDL-c), and cytokines (IL-1, IL-2, IL-4, IL-6, IL-10, TNF&#x003b1;, IFN&#x003b3;, and TGF&#x003b2;). Clinical, nutritional, and anthropometric assessments will take place immediately before starting the intervention and after 4 and 8&#x000a0;weeks during the study; lipid profile and cytokines will be evaluated before the intervention and at the end of 8&#x000a0;weeks. Each patient will be followed for 8&#x000a0;weeks.</p><p>Compliance with study treatment will be assessed by the 3-day treatment recall and the number of omega-3/placebo capsules returned. At every visit, the patients will be asked about the number of doses of the prescribed treatment that they did not take during the previous 3&#x000a0;days, and the ratio between the number of doses taken and the number prescribed will be calculated. The capsules will be dispensed at the beginning of the study and after 4&#x000a0;weeks, and the returned capsules will be verified at weeks 4 and 8.</p><p>The dietary omega-3 PUFA intake will be followed-up during the study (first visit and weeks 4 and 8) by analyzing the 24-h recall and 3-day food record, which are considered indirect methods of analyzing the diet, current dietary standards of a certain population, and their development over time [<xref ref-type="bibr" rid="B50">50</xref>].</p><p>Patients may be excluded from the study in case of complications during follow-up, such as significant changes in intestinal transit, use of anti-inflammatory drugs, and hospital admissions. Other complications will be assessed by the study team. All endpoints will be collected at time 0 and 8&#x000a0;weeks after omega-3/placebo supplementation starts.</p></sec><sec><title>Safety monitoring</title><p>Patients will be followed up by a multidisciplinary team at three time points: study start, week 4, and week 8. Possible complications will be assessed by the study cardiologist and pharmacist. The safety assessment will consist of monitoring adverse events, such as changes in the digestive tract, physical exams, and laboratory tests. Events, onset, and duration will be reported to the cardiologist, who will determine if it is necessary to suspend supplement use. Regular intake of omega-3 PUFAs is not a risk to health. According to the US Food and Drug Administration (FDA), the maximum intake of 3&#x000a0;g/day EPA&#x02009;+&#x02009;DHA is considered safe [<xref ref-type="bibr" rid="B51">51</xref>].</p></sec><sec><title>Randomization and concealment</title><p>After the screening phase, patients will be randomly assigned to 1 of 2 groups of 20 patients each: intervention group or control group. Assignment to either group will be performed by a computer-generated 1:1 randomization. This assignment will occur within randomly ordered blocks of size 4 or 6. This procedure will be conducted using R project software with package 'blockrand&#x02019; [<xref ref-type="bibr" rid="B52">52</xref>].</p><p>The allocation sequence will be concealed from the researchers, who will enroll and assess participants in sequentially numbered, opaque, sealed, stapled envelopes. To prevent subversion of the allocation sequence, the name and date of birth of the participant will be written on the envelope before the envelope is opened. The information in the envelope will be transferred onto the allocation card inside the envelope. Corresponding envelopes will be opened only after the enrolled participants have completed all baseline assessments and at the time of allocation to the intervention. These procedures will be carried out by a professional without access to the baseline evaluation results. The blister packaging and gel capsules of omega-3 PUFAs and placebo will be identical. They will be identified by the lot number on the package, which will be retained in the pharmacy, and only the blisters will be provided to patients. The pharmacist responsible for distribution and compliance assessment will be the only person who can access this information.</p></sec><sec><title>Blinding</title><p>The nutritionists and physician that will perform the initial evaluation before randomization, the monthly evaluations and anthropometric profile, and the final evaluation of the health care questionnaires after the end of the patient follow-up will be blinded to the patients&#x02019; assignments.</p></sec><sec><title>Statistical methods</title><p>The EpiData [<xref ref-type="bibr" rid="B53">53</xref>] and Statistical Package for Social Sciences [<xref ref-type="bibr" rid="B54">54</xref>] software will be used for data entry and analysis, respectively. For categorical data, we will use Pearson&#x02019;s &#x003c7;<sup>2</sup> or Fisher&#x02019;s exact test to verify the association between variables in the two groups (omega-3 and placebo). Statistical analysis will be performed by descriptive analysis, with numerical variables expressed as the mean and standard deviation (SD) or median and interquartile range. The Kolmogorov-Smirnov test will be used to test the normality of the sample distribution. The Student t test will be used in cases with a normal distribution to compare means between the two groups. The Wilcoxon test will be used in cases with a non-normal distribution. <italic>P</italic> values &#x0003c;0.05 will indicate a significant association in all of the statistical tests used.</p></sec><sec><title>Minimum sample size estimation</title><p>The minimum estimated sample size is 40 patients according to previous data, considering a prevalence of 60% of inadequate PUFA intake [<xref ref-type="bibr" rid="B55">55</xref>]. The following parameters were considered: baseline IFN&#x003b3;&#x02009;=&#x02009;3,986&#x02009;&#x000b1;&#x02009;738&#x000a0;pg/mL, IFN&#x003b3; after <italic>n</italic>-3 PUFA supplementation&#x02009;=&#x02009;2,922&#x02009;&#x000b1;&#x02009;1,275&#x000a0;pg/mL [<xref ref-type="bibr" rid="B56">56</xref>], power&#x02009;=&#x02009;0.8, and &#x003b1;&#x02009;=&#x02009;5%. We used the R project software with package 'Epicalc&#x02019; version 1.02 [<xref ref-type="bibr" rid="B57">57</xref>] to obtain this estimate.</p></sec><sec><title>Ethical issues</title><p>The study was approved by the Research Ethics committee of the Evandro Chagas Clinical Research Institute (IPEC/FIOCRUZ), registration number CAAE-0037.0.009.000-10 [<xref ref-type="bibr" rid="B58">58</xref>]. It is registered at ClinicalTrials.gov, number NCT01863576. All study supplies and data collected will be used exclusively in this study, and its results will be made public, whether they are favorable or not.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Omega-3 PUFA intake is associated with beneficial health effects. Omega-3 PUFAs are helpful in the prevention and treatment of pathologies such as inflammatory diseases, hypertension, hypertriglyceridemia, metabolic syndrome, and heart diseases. An Italian study of heart failure patients showed a reduction in mortality and hospital admissions due to cardiovascular events, suggesting beneficial effects of omega-3 PUFAs on the progression of heart disease [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Omega-3 administration is effective at treating hypertriglyceridemia. According to clinical trials, supplementation with 2 to 4&#x000a0;g of EPA/DHA per day may reduce triglyceride levels by 25% to 30% [<xref ref-type="bibr" rid="B59">59</xref>] by decreasing the liver synthesis of VLDL-c [<xref ref-type="bibr" rid="B34">34</xref>]. Omega-3 supplementation for chronic chagasic cardiomyopathy may be similar to other cardiomyopathies and promote reductions in triglyceride and VLDL-c levels.</p><p>Omega-3 has beneficial effects against heart cachexia after 18&#x000a0;weeks of supplementation [<xref ref-type="bibr" rid="B43">43</xref>]. Women with polycystic ovarian syndrome and BMI between 25 and 40&#x000a0;kg/m<sup>2</sup>, however, exhibited no significant changes in BMI after supplementation for 8&#x000a0;weeks [<xref ref-type="bibr" rid="B60">60</xref>]. The period of treatment in this study may not be long enough to observe significant anthropometric changes after omega-3 administration with no other associated instruction or intervention.</p><p>The action of omega-3 PUFAs is most likely related to their anti-inflammatory effects, which are not yet completely understood; however, it is known that omega-3 PUFA supplementation reduces arachidonic acid content in cell membranes, resulting in the synthesis of eicosanoids that are less inflammatory than the ones derived from omega-6 PUFAs [<xref ref-type="bibr" rid="B23">23</xref>]. Omega-3 PUFAs can also decrease activation of NF&#x003ba;B in response to inflammatory stimuli, such as lipopolysaccharide and inflammatory cytokines [<xref ref-type="bibr" rid="B22">22</xref>]. A meta-analysis of the effects of fish oil supplementation on the inflammatory markers of patients with chronic heart failure showed that circulating TNF&#x003b1;, IL-1, and IL-6 (proinflammatory cytokines) decreased after a supplementation period of 3 to 12&#x000a0;months with an EPA and DHA dose of 600 to 5,540&#x000a0;mg/day. These data suggest that supplementation with higher doses of omega-3 PUFAs or longer follow-up times are associated with more substantially decreased cytokines [<xref ref-type="bibr" rid="B61">61</xref>], which could benefit CCC patients.</p><p>A clinical trial evaluated 3-month omega-3 PUFA supplementation in patients with heart failure. Patients were divided into three groups: placebo, 1&#x000a0;g/day omega-3 PUFAs, and 4&#x000a0;g/day omega-3 PUFAs. Only the 4&#x000a0;g/day group had an improvement in ventricular function with an increase in the ejection fraction and endothelial function and a reduction in IL-6 [<xref ref-type="bibr" rid="B36">36</xref>]. We will use 3&#x000a0;g/day omega-3 PUFAs in our study based on recent results suggesting higher efficacy when compared to the usual 1&#x000a0;g dose, in addition to the fact that 3&#x000a0;g/day is considered safe by the FDA [<xref ref-type="bibr" rid="B51">51</xref>]. According to a recent American College of Cardiology and American Heart Association (ACC/AHA) Heart Failure Guideline, omega-3 supplementation is reasonable to use as adjunctive therapy in heart failure patients (Class of Recommendation IIa, Level of Evidence B ) [<xref ref-type="bibr" rid="B62">62</xref>].</p><p>The worse prognosis and progression of CCC are related to increased immune response with the production of proinflammatory cytokines and the inhibition of anti-inflammatory cytokines, which also occur in other cardiomyopathies [<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B64">64</xref>]. In Chagas disease, heart tissue is an important target of <italic>T. cruzi</italic> infection, and substantial amounts of proinflammatory cytokines, chemokines, and enzymes, including inducible nitric oxide synthase and metalloproteinases, are produced, resulting in inflammation and cardiac remodeling in response to parasite infection [<xref ref-type="bibr" rid="B65">65</xref>]. Higher levels of IFN&#x003b3; and TNF&#x003b1; are associated with lower levels of IL-4 and IL-10, in both cardiac and more severe forms of Chagas disease, and high levels of IL-10 or moderate levels of IFN&#x003b3; are associated with the indeterminate form [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B66">66</xref>]. Omega-3 and omega-6 PUFA intake may lead to an increase in IL-10 production, as shown in an experimental study in Wistar rats supplemented with ethyl-eicosapentaenoic acid and ethyl-&#x003b3;-linolenic acid compared to a group supplemented with palm oil [<xref ref-type="bibr" rid="B67">67</xref>]. Thus, omega-3 PUFA supplementation in CCC patients may lead to increased IL-4 and IL-10, reducing the inflammatory effect on heart tissue.</p><p>Omega-3 PUFA supplementation, due to its anti-inflammatory effects, is expected to decrease the serum levels of proinflammatory cytokines, which are associated with the proliferation of parasites and the fibrotic process characteristic of Chagas myocarditis. We thus suppose that the benefits to CCC patients with regard to the immunological profile could translate into a less severe progression of cardiomyopathy, with subsequent reduction in morbidity, in addition to secondary gains in the lipid profile.</p></sec><sec><title>Trial status</title><p>This study is currently recruiting patients.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>PSS, APdS and ASS conceived the study. GMSdS, AMH-M, PEAB, RMS, SSX, PSS, APdS and ASS participated in the study design. PSS, CSAC, CAF and PDB will recruit, select, and collect clinical data of the patients. PSS, ROP and GMSdS will randomize patients into the two arms of the protocol, deliver the proposed intervention, and collect data. PSS, PEAB, GMSdS and ASS will perform statistical analysis. APS is the study coordinator and ASS the principal investigator. PSS, GMSdS, PEAB, AMH-M and ASS helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>This study is funded by Evandro Chagas Clinical Research Institute.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Marcondes de Rezende</surname><given-names>J</given-names></name><article-title>American trypanosomiasis (Chagas disease)</article-title><source>Infect Dis Clin North Am</source><year>2012</year><volume>26</volume><fpage>275</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2012.03.002</pub-id><pub-id pub-id-type="pmid">22632639</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Marin-Neto</surname><given-names>JA</given-names></name><article-title>Chagas disease</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>1388</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60061-X</pub-id><pub-id pub-id-type="pmid">20399979</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><collab>Minist&#x000e9;rio da Sa&#x000fa;de. Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de</collab><article-title>Brazilian consensus on Chagas disease [in Portuguese]</article-title><source>Rev Soc Bras Med Trop</source><year>2005</year><volume>38</volume><issue>Suppl 3</issue><fpage>7</fpage><lpage>29</lpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Dias</surname><given-names>JC</given-names></name><article-title>The indeterminate form of human chronic Chagas&#x02019; disease: a clinical epidemiological review</article-title><source>Rev Soc Bras Med Trop</source><year>1989</year><volume>22</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1590/S0037-86821989000300007</pub-id><pub-id pub-id-type="pmid">2486527</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Biolo</surname><given-names>A</given-names></name><name><surname>Ribeiro</surname><given-names>AL</given-names></name><name><surname>Clausell</surname><given-names>N</given-names></name><article-title>Chagas cardiomyopathy - where do we stand after a hundred years?</article-title><source>Prog Cardiovasc Dis</source><year>2010</year><volume>52</volume><fpage>300</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2009.11.008</pub-id><pub-id pub-id-type="pmid">20109600</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Mady</surname><given-names>C</given-names></name><name><surname>Nacruth</surname><given-names>R</given-names></name><article-title>Natural history of chronic Chagas&#x02019; heart disease: prognosis factors</article-title><source>Sao Paulo Med J</source><year>1995</year><volume>113</volume><fpage>791</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1590/S1516-31801995000200009</pub-id><pub-id pub-id-type="pmid">8650478</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Marin Neto</surname><given-names>JA</given-names></name><name><surname>Sim&#x000f5;es</surname><given-names>MV</given-names></name><name><surname>Sarabanda</surname><given-names>AV</given-names></name><article-title>Chagas&#x02019; heart disease</article-title><source>Arq Bras Cardiol</source><year>1999</year><volume>72</volume><fpage>247</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">10513039</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Rassi</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>WC</given-names></name><article-title>Chagas&#x02019; heart disease</article-title><source>Clin Cardiol</source><year>2000</year><volume>23</volume><fpage>883</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1002/clc.4960231205</pub-id><pub-id pub-id-type="pmid">11129673</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Ribeiro</surname><given-names>AL</given-names></name><name><surname>Nunes</surname><given-names>MP</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><name><surname>Rocha</surname><given-names>MOC</given-names></name><article-title>Diagnosis and management of Chagas disease and cardiomyopathy</article-title><source>Nat Rev Cardiol</source><year>2012</year><volume>9</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2012.109</pub-id><pub-id pub-id-type="pmid">22847166</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Castro</surname><given-names>C</given-names></name><name><surname>Prata</surname><given-names>A</given-names></name><name><surname>Mac&#x000ea;do</surname><given-names>V</given-names></name><article-title>A folow-up period of 13&#x000a0;years prospective study in 190 chagasic patients of Mamba&#x000ed;, Goi&#x000e1;s, State, Brazil</article-title><source>Rev Soc Bras Med Trop</source><year>2001</year><volume>34</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">11562722</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Rocha</surname><given-names>MOC</given-names></name><name><surname>Ribeiro</surname><given-names>ALP</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><article-title>Clinical management of chronic Chagas cardiomyopathy</article-title><source>Front Biosci</source><year>2003</year><volume>8</volume><fpage>e44</fpage><lpage>e54</lpage><pub-id pub-id-type="doi">10.2741/926</pub-id><pub-id pub-id-type="pmid">12456332</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Punukollu</surname><given-names>G</given-names></name><name><surname>Gowda</surname><given-names>RM</given-names></name><name><surname>Khan</surname><given-names>IA</given-names></name><name><surname>Navarro</surname><given-names>VS</given-names></name><name><surname>Vasavada</surname><given-names>BC</given-names></name><article-title>Clinical aspects of the Chagas&#x02019; heart disease</article-title><source>Int J Cardiol</source><year>2007</year><volume>115</volume><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2006.03.004</pub-id><pub-id pub-id-type="pmid">16769134</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Gazzinelli</surname><given-names>RT</given-names></name><name><surname>Oswald</surname><given-names>IP</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Kullberg</surname><given-names>M</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Berzofsky</surname><given-names>JA</given-names></name><name><surname>Mosmann</surname><given-names>TR</given-names></name><name><surname>James</surname><given-names>SL</given-names></name><name><surname>Morse</surname><given-names>HC</given-names><suffix>3rd</suffix></name><article-title>Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection</article-title><source>Immunol Rev</source><year>1992</year><volume>127</volume><fpage>183</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.1992.tb01414.x</pub-id><pub-id pub-id-type="pmid">1354651</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Bahia-Oliveira</surname><given-names>LM</given-names></name><name><surname>Gomes</surname><given-names>JA</given-names></name><name><surname>Rocha</surname><given-names>MO</given-names></name><name><surname>Moreira</surname><given-names>MC</given-names></name><name><surname>Lemos</surname><given-names>EM</given-names></name><name><surname>Luz</surname><given-names>ZM</given-names></name><name><surname>Pereira</surname><given-names>ME</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>Dias</surname><given-names>JC</given-names></name><name><surname>Can&#x000e7;ado</surname><given-names>JR</given-names></name><name><surname>Gazzinelli</surname><given-names>G</given-names></name><name><surname>Corr&#x000ea;a-Oliveira</surname><given-names>R</given-names></name><article-title>IFN-gamma in human Chagas&#x02019; disease: protection or pathology?</article-title><source>Braz J Med Biol Res</source><year>1998</year><volume>31</volume><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">9686189</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Gomes</surname><given-names>JAS</given-names></name><name><surname>Bahia-Oliveira</surname><given-names>LMG</given-names></name><name><surname>Rocha</surname><given-names>MOC</given-names></name><name><surname>Martins-Filho</surname><given-names>OA</given-names></name><name><surname>Gazzinelli</surname><given-names>G</given-names></name><name><surname>Correa-Oliveira</surname><given-names>R</given-names></name><article-title>Evidence that development of severe cardiomyopathy in human Chagas&#x02019; disease is due to a Th1-specific immune response</article-title><source>Infect Immun</source><year>2003</year><volume>71</volume><fpage>1185</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.3.1185-1193.2003</pub-id><pub-id pub-id-type="pmid">12595431</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ara&#x000fa;jo-Jorge</surname><given-names>TC</given-names></name><name><surname>Waghabi</surname><given-names>MC</given-names></name><name><surname>de NC</surname><given-names>SM</given-names></name><name><surname>Keramidas</surname><given-names>M</given-names></name><name><surname>Bailly</surname><given-names>S</given-names></name><name><surname>Feige</surname><given-names>J-J</given-names></name><article-title>Pivotal role for TGF-beta in infectious heart disease: the case of <italic>Trypanosoma cruzi</italic> infection and consequent chagasic myocardiopathy</article-title><source>Cytokine Growth Factor Rev</source><year>2008</year><volume>19</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2008.08.002</pub-id><pub-id pub-id-type="pmid">18938102</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>P&#x000e9;rez-Fuentes</surname><given-names>R</given-names></name><name><surname>Gu&#x000e9;gan</surname><given-names>J-F</given-names></name><name><surname>Barnab&#x000e9;</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez-Colombo</surname><given-names>A</given-names></name><name><surname>Salgado-Rosas</surname><given-names>H</given-names></name><name><surname>Torres-Rasgado</surname><given-names>E</given-names></name><name><surname>Briones</surname><given-names>B</given-names></name><name><surname>Romero-D&#x000ed;az</surname><given-names>M</given-names></name><name><surname>Ramos-Jim&#x000e9;nez</surname><given-names>J</given-names></name><name><surname>S&#x000e1;nchez-Guill&#x000e9;n M del</surname><given-names>C</given-names></name><article-title>Severity of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals</article-title><source>Int J Parasitol</source><year>2003</year><volume>33</volume><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/S0020-7519(02)00283-7</pub-id><pub-id pub-id-type="pmid">12670514</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Dutra</surname><given-names>WO</given-names></name><name><surname>Rocha</surname><given-names>MOC</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><article-title>The clinical immunology of human Chagas disease</article-title><source>Trends Parasitol</source><year>2005</year><volume>21</volume><fpage>581</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2005.09.007</pub-id><pub-id pub-id-type="pmid">16236550</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Cunha-Neto</surname><given-names>E</given-names></name><name><surname>Nogueira</surname><given-names>LG</given-names></name><name><surname>Teixeira</surname><given-names>PC</given-names></name><name><surname>Ramasawmy</surname><given-names>R</given-names></name><name><surname>Drigo</surname><given-names>SA</given-names></name><name><surname>Goldberg</surname><given-names>AC</given-names></name><name><surname>Fonseca</surname><given-names>SG</given-names></name><name><surname>Bilate</surname><given-names>AM</given-names></name><name><surname>Kalil</surname><given-names>J</given-names></name><article-title>Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy</article-title><source>Mem Inst Oswaldo Cruz</source><year>2009</year><volume>104</volume><issue>Suppl 1</issue><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">19753481</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Perini</surname><given-names>J&#x000c2;DL</given-names></name><name><surname>Stevanato</surname><given-names>FB</given-names></name><name><surname>Sargi</surname><given-names>SC</given-names></name><name><surname>Visentainer</surname><given-names>JEL</given-names></name><name><surname>Dalalio</surname><given-names>MMDO</given-names></name><name><surname>Matshushita</surname><given-names>M</given-names></name><name><surname>Souza</surname><given-names>NED</given-names></name><name><surname>Visentainer</surname><given-names>JV</given-names></name><article-title>Omega-3 and omega-6 polyunsaturated fatty acids: metabolism in mammals and immune response</article-title><source>Rev Nutr</source><year>2010</year><volume>23</volume><fpage>1075</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1590/S1415-52732010000600013</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Simopoulos</surname><given-names>AP</given-names></name><article-title>Essential fatty acids in health and chronic disease</article-title><source>Am J Clin Nutr</source><year>1999</year><volume>70</volume><fpage>560S</fpage><lpage>569S</lpage><pub-id pub-id-type="pmid">10479232</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Calder</surname><given-names>PC</given-names></name><article-title>Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?</article-title><source>Br J Clin Pharmacol</source><year>2013</year><volume>75</volume><fpage>645</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">22765297</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Giugliano</surname><given-names>D</given-names></name><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Esposito</surname><given-names>K</given-names></name><article-title>The effects of diet on inflammation: emphasis on the metabolic syndrome</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.03.052</pub-id><pub-id pub-id-type="pmid">16904534</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>de Truchis</surname><given-names>P</given-names></name><name><surname>Kirstetter</surname><given-names>M</given-names></name><name><surname>Perier</surname><given-names>A</given-names></name><name><surname>Meunier</surname><given-names>C</given-names></name><name><surname>Zucman</surname><given-names>D</given-names></name><name><surname>Force</surname><given-names>G</given-names></name><name><surname>Doll</surname><given-names>J</given-names></name><name><surname>Katlama</surname><given-names>C</given-names></name><name><surname>Rozenbaum</surname><given-names>W</given-names></name><name><surname>Masson</surname><given-names>H</given-names></name><name><surname>Gardette</surname><given-names>J</given-names></name><name><surname>Melchior</surname><given-names>J-C</given-names></name><article-title>Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study</article-title><source>J Acquir Immune Defic Syndr</source><year>2007</year><volume>44</volume><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e31802c2f3d</pub-id><pub-id pub-id-type="pmid">17179770</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Thusgaard</surname><given-names>M</given-names></name><name><surname>Christensen</surname><given-names>JH</given-names></name><name><surname>M&#x000f8;rn</surname><given-names>B</given-names></name><name><surname>Andersen</surname><given-names>TS</given-names></name><name><surname>Vige</surname><given-names>R</given-names></name><name><surname>Arildsen</surname><given-names>H</given-names></name><name><surname>Schmidt</surname><given-names>EB</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><article-title>Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study</article-title><source>Scand J Infect Dis</source><year>2009</year><volume>41</volume><fpage>760</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1080/00365540903168056</pub-id><pub-id pub-id-type="pmid">19685375</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Fritsche</surname><given-names>KL</given-names></name><article-title>(n-3) Fatty acids and infectious disease resistance</article-title><source>J Nutr</source><year>2002</year><volume>132</volume><fpage>3566</fpage><lpage>3576</lpage><pub-id pub-id-type="pmid">12468590</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Trebble</surname><given-names>TM</given-names></name><name><surname>Wootton</surname><given-names>SA</given-names></name><name><surname>Miles</surname><given-names>EA</given-names></name><name><surname>Mullee</surname><given-names>M</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Ballinger</surname><given-names>AB</given-names></name><name><surname>Stroud</surname><given-names>MA</given-names></name><name><surname>Burdge</surname><given-names>GC</given-names></name><name><surname>Calder</surname><given-names>PC</given-names></name><article-title>Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>78</volume><fpage>376</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">12936918</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Damsgaard</surname><given-names>CT</given-names></name><name><surname>Fr&#x000f8;kiaer</surname><given-names>H</given-names></name><name><surname>Lauritzen</surname><given-names>L</given-names></name><article-title>The effects of fish oil and high or low linoleic acid intake on fatty acid composition of human peripheral blood mononuclear cells</article-title><source>Br J Nutr</source><year>2008</year><volume>99</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">17663804</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Damsgaard</surname><given-names>CT</given-names></name><name><surname>Lauritzen</surname><given-names>L</given-names></name><name><surname>Calder</surname><given-names>PC</given-names></name><name><surname>Kjaer</surname><given-names>TR</given-names></name><name><surname>Fr&#x000f8;kiaer</surname><given-names>H</given-names></name><article-title>Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men</article-title><source>J Nutr</source><year>2009</year><volume>139</volume><fpage>1410</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.3945/jn.108.102269</pub-id><pub-id pub-id-type="pmid">19494025</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Albert</surname><given-names>CM</given-names></name><name><surname>Campos</surname><given-names>H</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><article-title>Blood levels of long-chain n-3 fatty acids and the risk of sudden death</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>1113</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa012918</pub-id><pub-id pub-id-type="pmid">11948270</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Lemaitre</surname><given-names>RN</given-names></name><name><surname>King</surname><given-names>IB</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><article-title>n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>77</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">12540389</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Frenoux</surname><given-names>JM</given-names></name><name><surname>Prost</surname><given-names>ED</given-names></name><name><surname>Belleville</surname><given-names>JL</given-names></name><name><surname>Prost</surname><given-names>JL</given-names></name><article-title>A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats</article-title><source>J Nutr</source><year>2001</year><volume>131</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">11208936</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Tavazzi</surname><given-names>L</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Marchioli</surname><given-names>R</given-names></name><name><surname>Barlera</surname><given-names>S</given-names></name><name><surname>Franzosi</surname><given-names>MG</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Lucci</surname><given-names>D</given-names></name><name><surname>Nicolosi</surname><given-names>GL</given-names></name><name><surname>Porcu</surname><given-names>M</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><article-title>Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1223</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61239-8</pub-id><pub-id pub-id-type="pmid">18757090</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Sposito</surname><given-names>AC</given-names></name><name><surname>Caramelli</surname><given-names>B</given-names></name><name><surname>Fonseca</surname><given-names>FAH</given-names></name><name><surname>Bertolami</surname><given-names>MC</given-names></name><name><surname>Afiune Neto</surname><given-names>A</given-names></name><name><surname>Souza</surname><given-names>AD</given-names></name><name><surname>Lottenberg</surname><given-names>AMP</given-names></name><name><surname>Chacra</surname><given-names>AP</given-names></name><name><surname>Faludi</surname><given-names>AA</given-names></name><name><surname>Loures-Vale</surname><given-names>AA</given-names></name><name><surname>Carvalho</surname><given-names>AC</given-names></name><name><surname>Duncan</surname><given-names>B</given-names></name><name><surname>Gelonese</surname><given-names>B</given-names></name><name><surname>Polanczyk</surname><given-names>C</given-names></name><name><surname>Rodrigues Sobrinho</surname><given-names>CRM</given-names></name><name><surname>Scherr</surname><given-names>C</given-names></name><name><surname>Karla</surname><given-names>C</given-names></name><name><surname>Armaganijan</surname><given-names>D</given-names></name><name><surname>Moriguchi</surname><given-names>E</given-names></name><name><surname>Saraiva</surname><given-names>F</given-names></name><name><surname>Pichetti</surname><given-names>G</given-names></name><name><surname>Xavier</surname><given-names>HT</given-names></name><name><surname>Chaves</surname><given-names>H</given-names></name><name><surname>Borges</surname><given-names>JL</given-names></name><name><surname>Diament</surname><given-names>J</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>JI</given-names></name><name><surname>Nicolau</surname><given-names>JC</given-names></name><name><surname>Dos Santos</surname><given-names>JE</given-names></name><name><surname>de Lima</surname><given-names>JJG</given-names></name><name><surname>Vieira</surname><given-names>JL</given-names></name><article-title>IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology [in Portuguese]</article-title><source>Arq Bras Cardiol</source><year>2007</year><volume>88</volume><issue>Suppl 1</issue><fpage>2</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17515982</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>McMurray</surname><given-names>DN</given-names></name><name><surname>Chapkin</surname><given-names>RS</given-names></name><article-title>n-3 polyunsaturated fatty acids-physiological relevance of dose</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2010</year><volume>82</volume><fpage>155</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2010.02.028</pub-id><pub-id pub-id-type="pmid">20188532</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Moertl</surname><given-names>D</given-names></name><name><surname>Hammer</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Hutuleac</surname><given-names>R</given-names></name><name><surname>Vonbank</surname><given-names>K</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><article-title>Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study</article-title><source>Am Heart J</source><year>2011</year><volume>161</volume><fpage>e1</fpage><lpage>e9</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2010.10.021</pub-id><pub-id pub-id-type="pmid">21570522</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>MP</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><article-title>Tolerability of omega-3 fatty acid supplements in perinatal women</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2007</year><volume>77</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2007.09.004</pub-id><pub-id pub-id-type="pmid">17981449</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Faber</surname><given-names>J</given-names></name><name><surname>Berkhout</surname><given-names>M</given-names></name><name><surname>Fiedler</surname><given-names>U</given-names></name><name><surname>Avlar</surname><given-names>M</given-names></name><name><surname>Witteman</surname><given-names>BJ</given-names></name><name><surname>Vos</surname><given-names>AP</given-names></name><name><surname>Henke</surname><given-names>M</given-names></name><name><surname>Garssen</surname><given-names>J</given-names></name><name><surname>van Helvoort</surname><given-names>A</given-names></name><name><surname>Otten</surname><given-names>MH</given-names></name><name><surname>Arends</surname><given-names>J</given-names></name><article-title>Rapid EPA and DHA incorporation and reduced PGE(2) levels after one week intervention with a medical food in cancer patients receiving radiotherapy, a randomized trial</article-title><source>Clin Nutr</source><year>2013</year><volume>32</volume><fpage>338</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2012.09.009</pub-id><pub-id pub-id-type="pmid">23123043</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Vieira</surname><given-names>MJ</given-names></name><name><surname>Gama-Rodrigues</surname><given-names>JJ</given-names></name><name><surname>Habr-Gama</surname><given-names>A</given-names></name><name><surname>Faintuch</surname><given-names>J</given-names></name><name><surname>Waitzberg</surname><given-names>DL</given-names></name><name><surname>Pinotti</surname><given-names>HW</given-names></name><article-title>Preoperative assessment in cases of adult megacolon suffering from moderate malnutrition</article-title><source>Nutrition</source><year>1996</year><volume>12</volume><fpage>491</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/S0899-9007(96)91724-4</pub-id><pub-id pub-id-type="pmid">8878140</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Penhavel</surname><given-names>FAS</given-names></name><name><surname>Waitzberg</surname><given-names>DL</given-names></name><name><surname>Trevenzol</surname><given-names>HP</given-names></name><name><surname>Alves</surname><given-names>L</given-names></name><name><surname>Zilberstein</surname><given-names>B</given-names></name><name><surname>Gama-Rodrigues</surname><given-names>J</given-names></name><article-title>Pre-and postoperative nutritional evaluation in patients with chagasic megaesophagus</article-title><source>Nutr Hosp</source><year>2004</year><volume>19</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15049410</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Celano</surname><given-names>RMG</given-names></name><name><surname>Ebram Neto</surname><given-names>J</given-names></name><name><surname>Bottoni</surname><given-names>A</given-names></name><name><surname>Gagliardi</surname><given-names>D</given-names></name><article-title>Pre- operatory nutritional evaluation of patients with non-advanced megaesophagus</article-title><source>Rev Col Bras Cir</source><year>2007</year><volume>34</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1590/S0100-69912007000300003</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Geraix</surname><given-names>J</given-names></name><name><surname>Ardisson</surname><given-names>LP</given-names></name><name><surname>Marcondes-Machado</surname><given-names>J</given-names></name><name><surname>Pereira</surname><given-names>PCM</given-names></name><article-title>Clinical and nutritional profile of individuals with Chagas disease</article-title><source>Braz J Infect Dis</source><year>2007</year><volume>11</volume><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1590/S1413-86702007000400008</pub-id><pub-id pub-id-type="pmid">17873995</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Ventura</surname><given-names>HO</given-names></name><name><surname>Milani</surname><given-names>RV</given-names></name><article-title>Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure</article-title><source>J Heart Lung Transplant</source><year>2006</year><volume>25</volume><fpage>834</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2006.03.005</pub-id><pub-id pub-id-type="pmid">16818127</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Friedewald</surname><given-names>WT</given-names></name><name><surname>Levy</surname><given-names>RI</given-names></name><name><surname>Fredrickson</surname><given-names>DS</given-names></name><article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title><source>Clin Chem</source><year>1972</year><volume>18</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Frisancho</surname><given-names>AR</given-names></name><article-title>New norms of upper limb fat and muscle areas for assessment of nutritional status</article-title><source>Am J Clin Nutr</source><year>1981</year><volume>34</volume><fpage>2540</fpage><lpage>2545</lpage><pub-id pub-id-type="pmid">6975564</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="book"><name><surname>Frisancho</surname><given-names>AR</given-names></name><source>Anthropometric Standards for the Assessment of Growth and Nutritional Status</source><year>1990</year><publisher-name>Ann Arbor, MI: University of Michigan</publisher-name></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Murphy</surname><given-names>PM</given-names></name><name><surname>Blackshaw</surname><given-names>GRJC</given-names></name><name><surname>Paris</surname><given-names>HJ</given-names></name><name><surname>Edwards</surname><given-names>P</given-names></name><name><surname>Barry</surname><given-names>JD</given-names></name><name><surname>Lewis</surname><given-names>WG</given-names></name><article-title>Prospective evaluation of nutritional status related to body mass indices and outcomes after modified D2 gastrectomy for carcinoma</article-title><source>Clin Nutr</source><year>2004</year><volume>23</volume><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2003.07.009</pub-id><pub-id pub-id-type="pmid">15297082</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>FE</given-names></name><name><surname>Byers</surname><given-names>T</given-names></name><article-title>Dietary assessment resource manual</article-title><source>J Nutr</source><year>1994</year><volume>124</volume><fpage>2245S</fpage><lpage>2317S</lpage><pub-id pub-id-type="pmid">7965210</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Hebert</surname><given-names>JR</given-names></name><name><surname>Gupta</surname><given-names>PC</given-names></name><name><surname>Bhonsle</surname><given-names>RB</given-names></name><name><surname>Sinor</surname><given-names>PN</given-names></name><name><surname>Mehta</surname><given-names>H</given-names></name><name><surname>Mehta</surname><given-names>FS</given-names></name><article-title>Development and testing of a quantitative food frequency questionnaire for use in Gujarat, India</article-title><source>Public Health Nutr</source><year>1999</year><volume>2</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10452730</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Monteiro</surname><given-names>CA</given-names></name><name><surname>Mondini</surname><given-names>L</given-names></name><name><surname>Costa</surname><given-names>RB</given-names></name><article-title>Secular changes in dietary patterns in the metropolitan areas of Brazil (1988&#x02013;1996)</article-title><source>Rev Saude Publica</source><year>2000</year><volume>34</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1590/S0034-89102000000300007</pub-id><pub-id pub-id-type="pmid">10920447</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Harris</surname><given-names>WS</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Lefevre</surname><given-names>M</given-names></name><name><surname>Toner</surname><given-names>CD</given-names></name><name><surname>Colombo</surname><given-names>J</given-names></name><name><surname>Cunnane</surname><given-names>SC</given-names></name><name><surname>Holden</surname><given-names>JM</given-names></name><name><surname>Klurfeld</surname><given-names>DM</given-names></name><name><surname>Morris</surname><given-names>MC</given-names></name><name><surname>Whelan</surname><given-names>J</given-names></name><article-title>Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids</article-title><source>J Nutr</source><year>2009</year><volume>139</volume><fpage>804S</fpage><lpage>819S</lpage><pub-id pub-id-type="doi">10.3945/jn.108.101329</pub-id><pub-id pub-id-type="pmid">19244379</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="book"><collab>R Core Team</collab><source>R: A Language and Environment for Statistical Computing</source><year>2013</year><publisher-name>Vienna, Austria: R Foundation for Statistical Computing</publisher-name></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="book"><name><surname>Lauritsen</surname><given-names>JM</given-names></name><name><surname>Bruus</surname><given-names>M</given-names></name><source>EpiData (version 3). A Comprehensive Tool for Validated Entry and Documentation of Data</source><year>2003</year><publisher-name>Odense, Denmark: The EpiData Association</publisher-name></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="other"><collab>SPSS Inc</collab><source>SPSS for Windows, Version 16.0</source><comment>[<ext-link ext-link-type="uri" xlink:href="http://www-01.ibm.com/support/docview.wss?uid=swg21476197">http://www-01.ibm.com/support/docview.wss?uid=swg21476197</ext-link>]</comment></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Salvador</surname><given-names>MB</given-names></name><name><surname>Sarkis</surname><given-names>KS</given-names></name><name><surname>Silva</surname><given-names>RG</given-names></name><name><surname>Zerbini CA de</surname><given-names>F</given-names></name><name><surname>Martini</surname><given-names>LA</given-names></name><article-title>Avalia&#x000e7;&#x000e3;o da ingest&#x000e3;o de &#x000e1;cidos graxos, antioxidantes e da composi&#x000e7;&#x000e3;o corporal em mulheres com artrite reumat&#x000f3;ide [Fatty acids, antioxidants and body composition evaluation in woman with reumathoid arthritis]</article-title><source>Nutrire Rev Soc Bras Aliment Nutr</source><year>2008</year><volume>33</volume><fpage>17</fpage><lpage>30</lpage></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Kew</surname><given-names>S</given-names></name><name><surname>Mesa</surname><given-names>MD</given-names></name><name><surname>Tricon</surname><given-names>S</given-names></name><name><surname>Buckley</surname><given-names>R</given-names></name><name><surname>Minihane</surname><given-names>AM</given-names></name><name><surname>Yaqoob</surname><given-names>P</given-names></name><article-title>Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>79</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">15051614</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="other"><name><surname>Chongsuvivatwong</surname><given-names>V</given-names></name><article-title>Epicalc: epidemiological calculator</article-title><comment>[<ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/web/packages/epicalc/epicalc.pdf">http://cran.r-project.org/web/packages/epicalc/epicalc.pdf</ext-link>]</comment></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="other"><collab>Government of Brazil</collab><article-title>The National Committee for Ethics in Research-MOH (CONEP/MS)</article-title><comment>[<ext-link ext-link-type="uri" xlink:href="http://conselho.saude.gov.br/web_comissoes/conep/index.html">http://conselho.saude.gov.br/web_comissoes/conep/index.html</ext-link>]</comment></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>RD</given-names></name><name><surname>Gagliardi</surname><given-names>ACM</given-names></name><name><surname>Xavier</surname><given-names>HT</given-names></name><name><surname>Magnoni</surname><given-names>CD</given-names></name><name><surname>Cassani</surname><given-names>R</given-names></name><name><surname>Lottenberg</surname><given-names>AM</given-names></name><name><surname>Casella</surname><given-names>A</given-names></name><name><surname>Araujo</surname><given-names>DB</given-names></name><name><surname>Cesena</surname><given-names>FY</given-names></name><name><surname>Alves</surname><given-names>RJ</given-names></name><name><surname>Faludi</surname><given-names>AA</given-names></name><name><surname>Geloneze</surname><given-names>B</given-names></name><name><surname>Scherr</surname><given-names>C</given-names></name><name><surname>Kovacs</surname><given-names>C</given-names></name><name><surname>Tomazzela</surname><given-names>C</given-names></name><name><surname>Carla</surname><given-names>C</given-names></name><name><surname>Barrera-Arellano</surname><given-names>D</given-names></name><name><surname>Cintra</surname><given-names>D</given-names></name><name><surname>Quint&#x000e3;o</surname><given-names>E</given-names></name><name><surname>Nakandakare</surname><given-names>ER</given-names></name><name><surname>Fonseca</surname><given-names>FAH</given-names></name><name><surname>Pimentel</surname><given-names>I</given-names></name><name><surname>Santos</surname><given-names>JE</given-names></name><name><surname>Bertolami</surname><given-names>MC</given-names></name><name><surname>Rogero</surname><given-names>M</given-names></name><name><surname>Izar</surname><given-names>MCO</given-names></name><name><surname>Nakasato</surname><given-names>M</given-names></name><name><surname>Damasceno</surname><given-names>NRT</given-names></name><name><surname>Maranh&#x000e3;o</surname><given-names>R</given-names></name><name><surname>Cassani</surname><given-names>RSL</given-names></name><name><surname>Perim</surname><given-names>R</given-names></name><name><surname>Ramos</surname><given-names>S</given-names></name><article-title>I Diretriz sobre o consumo de gorduras e sa&#x000fa;de cardiovascular [in Portuguese]</article-title><source>Arq Bras Cardiol</source><year>2013</year><volume>100</volume><fpage>1</fpage><lpage>40</lpage></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Rafraf</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>E</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M</given-names></name><name><surname>Farzadi</surname><given-names>L</given-names></name><article-title>Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome</article-title><source>J Am Coll Nutr</source><year>2012</year><volume>31</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1080/07315724.2012.10720443</pub-id><pub-id pub-id-type="pmid">23529993</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Xin</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><article-title>Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials</article-title><source>BMC Cardiovasc Disord</source><year>2012</year><volume>12</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/1471-2261-12-77</pub-id><pub-id pub-id-type="pmid">22994912</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Yancy</surname><given-names>CW</given-names></name><name><surname>Jessup</surname><given-names>M</given-names></name><name><surname>Bozkurt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Casey</surname><given-names>DE</given-names></name><name><surname>Drazner</surname><given-names>MH</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Geraci</surname><given-names>SA</given-names></name><name><surname>Horwich</surname><given-names>T</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Kasper</surname><given-names>EK</given-names></name><name><surname>Levy</surname><given-names>WC</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>McBride</surname><given-names>PE</given-names></name><name><surname>McMurray</surname><given-names>JJV</given-names></name><name><surname>Mitchell</surname><given-names>JE</given-names></name><name><surname>Peterson</surname><given-names>PN</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><name><surname>Sam</surname><given-names>F</given-names></name><name><surname>Stevenson</surname><given-names>LW</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Tsai</surname><given-names>EJ</given-names></name><name><surname>Wilkoff</surname><given-names>BL</given-names></name><article-title>ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title><source>Circulation</source><year>2013</year><volume>128</volume><fpage>e240</fpage><lpage>e327</lpage><pub-id pub-id-type="pmid">23741058</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Rocha Rodrigues</surname><given-names>DB</given-names></name><name><surname>dos Reis</surname><given-names>MA</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>Pereira SA de</surname><given-names>L</given-names></name><name><surname>de PA</surname><given-names>TV</given-names></name><name><surname>Tostes</surname><given-names>PA</given-names><suffix>Jr</suffix></name><name><surname>Rodrigues</surname><given-names>V</given-names><suffix>Jr</suffix></name><article-title><italic>In situ</italic> expression of regulatory cytokines by heart inflammatory cells in Chagas&#x02019; disease patients with heart failure</article-title><source>Clin Dev Immunol</source><year>2012</year><volume>2012</volume><fpage>361730</fpage><pub-id pub-id-type="pmid">22811738</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Guedes</surname><given-names>PMM</given-names></name><name><surname>Gutierrez</surname><given-names>FRS</given-names></name><name><surname>Silva</surname><given-names>GK</given-names></name><name><surname>Dellalibera-Joviliano</surname><given-names>R</given-names></name><name><surname>Rodrigues</surname><given-names>GJ</given-names></name><name><surname>Bendhack</surname><given-names>LM</given-names></name><name><surname>Rassi</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Maciel</surname><given-names>BC</given-names></name><name><surname>Marin Neto</surname><given-names>JA</given-names></name><name><surname>Silva</surname><given-names>JS</given-names></name><article-title>Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas&#x02019; disease</article-title><source>PLoS Negl Trop Dis</source><year>2012</year><volume>6</volume><fpage>e1630</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0001630</pub-id><pub-id pub-id-type="pmid">22545173</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Corr&#x000ea;a-Oliveira</surname><given-names>R</given-names></name><name><surname>Gomes</surname><given-names>J</given-names></name><name><surname>Lemos</surname><given-names>EM</given-names></name><name><surname>Cardoso</surname><given-names>GM</given-names></name><name><surname>Reis</surname><given-names>DD</given-names></name><name><surname>Adad</surname><given-names>S</given-names></name><name><surname>Crema</surname><given-names>E</given-names></name><name><surname>Martins-Filho</surname><given-names>OA</given-names></name><name><surname>Costa</surname><given-names>MO</given-names></name><name><surname>Gazzinelli</surname><given-names>G</given-names></name><name><surname>Bahia-Oliveira</surname><given-names>LM</given-names></name><article-title>The role of the immune response on the development of severe clinical forms of human Chagas disease</article-title><source>Mem Inst Oswaldo Cruz</source><year>1999</year><volume>94</volume><issue>Suppl 1</issue><fpage>253</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">10677728</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Penas</surname><given-names>F</given-names></name><name><surname>Mirkin</surname><given-names>GA</given-names></name><name><surname>Hovsepian</surname><given-names>E</given-names></name><name><surname>Cevey</surname><given-names>A</given-names></name><name><surname>Caccuri</surname><given-names>R</given-names></name><name><surname>Sales</surname><given-names>ME</given-names></name><name><surname>Goren</surname><given-names>NB</given-names></name><article-title>PPAR&#x003b3; ligand treatment inhibits cardiac inflammatory mediators induced by infection with different lethality strains of Trypanosoma cruzi</article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1832</volume><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2012.08.007</pub-id><pub-id pub-id-type="pmid">22917565</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Leonard</surname><given-names>BE</given-names></name><name><surname>Horrobin</surname><given-names>DF</given-names></name><article-title>Effects of dietary n-3 or n-6 fatty acids on interleukin-1&#x003b2;-induced anxiety, stress, and inflammatory responses in rats</article-title><source>J Lipid Res</source><year>2003</year><volume>44</volume><fpage>1984</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1194/jlr.M300217-JLR200</pub-id><pub-id pub-id-type="pmid">12837849</pub-id></mixed-citation></ref></ref-list></back></article>